Biological characteristics of chronic eosinophilic leukemia cells with a t(2;5)(p23;q35) translocation

Leukemia & Lymphoma
H SatoA Yuo

Abstract

We studied the biological features of eosinophils in a patient with chronic eosinophilic leukemia and a unique t(2:5)(p23;q35) translocation. Microscopic and cytochemical studies revealed no particular abnormalities, although more than 90% of the peripheral eosinophils had a density lighter than 1.080 g/ml. Clonogenic assay disclosed that myeloid progenitor cells possessed the translocation, although in vitro eosinophilopoiesis seemed normal, and there were also hematopoietic cells with a normal karyotype. In a surface marker study, EG1 was positive on 34.0% of the eosinophils, while EG2 positivity was only 0.5%. Eosinophilopoietic growth factors and adhesion molecules were virtually absent with the exception of GM-CSF and CD11b. Functional studies showed that chemotaxis for C5a was normal, although that for IL-2 or FMLP was attenuated. In addition, leukotriene C4 production was decreased while O2- production was intact. These findings indicated that our patient's eosinophils were not in an activated state despite their extreme hypodensity, and suggested that the leukemic eosinophils had slight defects of cellular function. These characteristics may have saved the patient from the multiple organ damage which occurs in typical h...Continue Reading

References

Dec 1, 1977·The American Journal of Medicine·J D BitranJ E Ultmann
Jan 1, 1992·Clinical Immunology and Immunopathology·P F Weller
Sep 1, 1991·The Journal of Clinical Investigation·T H RandP F Weller
Jan 1, 1991·Clinical and Laboratory Haematology·P Yates, M N Potter
Apr 18, 1991·The New England Journal of Medicine·P F Weller
May 1, 1988·Cancer Genetics and Cytogenetics·M A da SilvaR Hoffman
Apr 15, 1986·Cancer Genetics and Cytogenetics·A BroustetJ Reiffers
Apr 1, 1986·British Journal of Haematology·L ParreiraD Catovsky
Mar 1, 1985·Cancer Genetics and Cytogenetics·K MaedaD L VanDyke
Aug 1, 1972·Annals of Internal Medicine·E P FlanneryJ L Bedynek
Dec 1, 1980·The Journal of Clinical Investigation·D A BassC E McCall
Jun 1, 1994·British Journal of Haematology·H SatoM Morita
Jan 1, 1993·Acta Haematologica·W HiguchiA Shibata
Dec 19, 1964·Lancet·G L KAUER, R L ENGLE

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.